The genetic basis of progression in multiple sclerosis
多发性硬化症进展的遗传基础
基本信息
- 批准号:9737736
- 负责人:
- 金额:$ 44.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAffectAgeBenignBioinformaticsBiological AssayBiological ProcessCellsCentral Nervous System DiseasesClinicalCollaborationsCountryDNADataData SetDevelopmentDiseaseDisease ProgressionFaceFutureGenerationsGenesGeneticGenetic DeterminismGenetic ScreeningGenotypeGoalsIn VitroIndividualInflammatoryInstitutesInternationalJointsMasksMeasuresMeta-AnalysisMultiple SclerosisNerve DegenerationNervous System PhysiologyOutcomePathogenesisPathway AnalysisPathway interactionsPatientsPhasePlayPopulationProbabilityRelapseResearchResourcesRunningSamplingSeveritiesStatistical Data InterpretationSubgroupSwedenSystemTherapeuticTissuesValidationVariantagedbioinformatics pipelinecell typecohortcost effectivedesigndisabilitygenetic informationgenetic variantgenome wide association studygenome-wideillness lengthin silicoindividual patientinnovationinsightinterestmultiple sclerosis patientoutcome forecastpatient populationprognosticprogramsscreeningsuccess
项目摘要
This proposal will seek to identify and characterize the genetic factors that modulate disease activity and
progression in multiple sclerosis (MS). The project builds on the hypothesis that allelic variants affecting
disease trajectory are eminently identifiable through adequately powered unbiased genetic screens, and will
thus employ a multi-dimensional statistical analysis to identify key gene networks and biological processes
underlying disease progression. In order to minimize the confounding influence of the temporary fluctuations in
disability that result from the relapsing inflammatory activity that characterizes the early stages of MS the
discovery phase of this project will focus exclusively on older subjects (aged at least 55) with a long disease
duration (>10 years). Since typically less than 1 in 7 patients satisfy these criteria this approach is only
possible because of the enormous bio-specimen resource available to the International Multiple Sclerosis
Genetics Consortium (IMSGC) (>62,000 cases). We will use the Multiple Sclerosis Severity Score (MSSS) as
our measure of progression; an ordinal decile score that indicates how a patient's Expanded Disability Status
Scale (EDSS) ranks in comparison with other patients with the same duration of disease. The IMSGC has DNA
from almost 9,000 older long disease duration patients that have at least one MSSS measure. For maximal
efficiency we will screen these 9,000 cases in collaboration with our colleagues from the Karolinska Institute in
Sweden. Replicated results will be immediately analyzed in the context of cell-specific pathways and top
candidates will be subsequently explored for genetic interactions, including their functional validation.
Specifically, in Aim 1 we will conduct a GWAS on 4,000 patients using the latest generation of genotyping
chips, which through imputation will allow us to assess more than 70 million variants. In Specific Aim 2 we will
then replicate the most associated markers identified in aim 1 in the remaining 5,000 samples, conduct
additional replications in at least two more independent sample populations, a meta-analysis, and perform
bioinformatics and experimental validation of the most promising associations. Combining the data across both
efforts will provide power to identify variants accounting for as little as 0.5% of variances in MSSS. The
identification of genetic modifiers of disease expression will have profound translational implications for the
understanding and management of MS, and in particular for progressive MS, the most disabling and currently
untreatable form of the disease.
该提案将寻求确定和描述调节疾病活动的遗传因素,
多发性硬化症(MS)的进展。该项目建立在等位基因变异影响
疾病的轨迹是非常明确的识别,通过足够有力的无偏见的遗传筛选,
从而采用多维统计分析来识别关键基因网络和生物过程
基础疾病进展。为了尽量减少临时波动的混杂影响,
由于MS早期阶段特征性的复发性炎症活动而导致的残疾,
该项目的发现阶段将专门关注患有长期疾病的老年受试者(至少55岁)
持续时间(>10年)。由于通常只有不到七分之一的患者满足这些标准,因此这种方法只是
这是因为国际多发性硬化症组织拥有大量的生物标本资源,
遗传学联合会(IMSGC)(> 62 000例)。我们将使用多发性硬化严重程度评分(MSSS)作为
我们的进展指标;一个有序的十分位数分数,表明患者的扩展残疾状态
量表(EDSS)与其他具有相同病程的患者相比进行排名。IMSGC有DNA
来自近9,000名至少有一项MSSS指标的老年长期疾病患者。用于最大
为了提高效率,我们将与卡罗林斯卡医学院的同事合作,
瑞典.重复的结果将立即在细胞特异性途径的背景下进行分析,
随后将探讨候选基因的相互作用,包括其功能验证。
具体来说,在目标1中,我们将使用最新一代基因分型技术对4,000名患者进行GWAS。
芯片,通过估算,它将使我们能够评估超过7000万个变体。具体目标2
然后在剩下的5,000个样本中复制目标1中确定的最相关的标记,
在至少两个更独立的样本群体中进行额外的重复,进行荟萃分析,并进行
生物信息学和实验验证最有前途的协会。将两者的数据结合起来
这些努力将提供识别变异的能力,变异仅占MSSS变异的0.5%。的
疾病表达的遗传修饰物的鉴定将对疾病的发生和发展具有深远的翻译意义。
理解和管理MS,特别是对于进行性MS,最禁用和目前
无法治愈的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SERGIO E BARANZINI其他文献
SERGIO E BARANZINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SERGIO E BARANZINI', 18)}}的其他基金
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10330633 - 财政年份:2020
- 资助金额:
$ 44.3万 - 项目类别:
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10547256 - 财政年份:2020
- 资助金额:
$ 44.3万 - 项目类别:
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10706762 - 财政年份:2020
- 资助金额:
$ 44.3万 - 项目类别:
EVIDARA: Automated Evidential Support from Raw Data for relay agents in Biomedical KG Queries
EVIDARA:生物医学 KG 查询中中继代理的原始数据自动证据支持
- 批准号:
10057190 - 财政年份:2020
- 资助金额:
$ 44.3万 - 项目类别:
The genetic basis of progression in multiple sclerosis
多发性硬化症进展的遗传基础
- 批准号:
10084323 - 财政年份:2017
- 资助金额:
$ 44.3万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
8925166 - 财政年份:2014
- 资助金额:
$ 44.3万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
9116321 - 财政年份:2014
- 资助金额:
$ 44.3万 - 项目类别:
Post GWAS approach to identify cell-specific genetic pathways underlying MS risk
GWAS 后方法可识别 MS 风险背后的细胞特异性遗传途径
- 批准号:
9330939 - 财政年份:2014
- 资助金额:
$ 44.3万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 44.3万 - 项目类别:
Research Grant